Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:03:32.603Z.
Calculation as of: 2026-10-06T21:03:32.603Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a19952d2edecd783a1a7aa32ab0a3489a492a6ad3733958836c0f0d47bc8061
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Spruce Biosciences, Inc.
Market Cap
$117.76M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | $117.76M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | N/A |
| Cibus, Inc. (CBUS)vs › | $119.84M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A |
| Seer, Inc. (SEER)vs › | $120.41M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
